ONDANSETRON VIATRIS ondansetron (as hydrochloride dihydrate) 4 mg/2 mL solution for injection ampoule Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

ondansetron viatris ondansetron (as hydrochloride dihydrate) 4 mg/2 ml solution for injection ampoule

alphapharm pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium citrate dihydrate; sodium chloride - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

CYCLOBENZAPRINE HYDROCHLORIDE- cyclobenzaprine hydrochloride tablet, film coated Spojené štáty - angličtina - NLM (National Library of Medicine)

cyclobenzaprine hydrochloride- cyclobenzaprine hydrochloride tablet, film coated

clinical solutions wholesale - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 10 mg - cyclobenzaprine hydrochloride is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. cyclobenzaprine hydrochloride should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamine oxidase (mao) inhibitors or within 14 days after their dis

HYDROXYZINE HYDROCHLORIDE syrup Spojené štáty - angličtina - NLM (National Library of Medicine)

hydroxyzine hydrochloride syrup

pharmaceutical associates, inc. - hydroxyzine hydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - hydroxyzine hydrochloride 10 mg in 5 ml - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. as a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. oral hydroxyzine hydrochloride i

SILDATIO PHT sildenafil (as citrate) 20 mg film-coated tablets blister pack Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sildatio pht sildenafil (as citrate) 20 mg film-coated tablets blister pack

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate; hypromellose; croscarmellose sodium; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

ANTACID FRUIT CHEWS- calcium carbonate tablet, chewable Spojené štáty - angličtina - NLM (National Library of Medicine)

antacid fruit chews- calcium carbonate tablet, chewable

family dollar - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) - calcium carbonate 750 mg - purpose antacid uses relieves heartburn sour stomach acid indigestion upset stomach due to these symptoms

ANTACID FRUIT FLAVOR CHEWS- calcium carbonate lozenge Spojené štáty - angličtina - NLM (National Library of Medicine)

antacid fruit flavor chews- calcium carbonate lozenge

family dollar - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) - calcium carbonate 750 mg - purpose antacid uses relieves heartburn sour stomach acid indigestion upset stomach due to these symptoms

OXYMORPHONE HYDROCHLORIDE- oxymorphone hydrochloride tablet, film coated, extended release Spojené štáty - angličtina - NLM (National Library of Medicine)

oxymorphone hydrochloride- oxymorphone hydrochloride tablet, film coated, extended release

lake erie medical dba quality care products llc - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 20 mg - oxymorphone hydrochloride extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of usage - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve oxymorphone hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - oxymorphone hydrochloride extended-release tablets are not indicated as an as-needed (prn) analgesic. oxymorphone hydrochloride extended-release tablets are contraindicated in patients with: - significant respiratory depression - acute or severe bronchial asthma or hypercarbia - known or suspe

METHYLPHENIDATE HYDROCHLORIDE tablet, chewable Spojené štáty - angličtina - NLM (National Library of Medicine)

methylphenidate hydrochloride tablet, chewable

camber pharmaceuticals inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 2.5 mg - attention deficit disorders, narcolepsy attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride chewable tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central

LIDOCAINE HYDROCHLORIDE injection Spojené štáty - angličtina - NLM (National Library of Medicine)

lidocaine hydrochloride injection

medical purchasing solutions, llc - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - lidocaine hydrochloride administered intravenously, is specifically indicated in the acute management of ventricular arrhythmias such as those occurring in relation to acute myocardial infarction, or during cardiac manipulation, such as cardiac surgery. lidocaine hydrochloride is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. lidocaine hydrochloride should not be used in patients with stokes-adams syndrome. wolff-parkinson-white syndrome, or with severe degrees of sinoatrial, atrioventricular, or intraventricular block in the absence of an artificial pacemaker. although specific studies have not been conducted, lidocaine hydrochloride has been used clinically without evidence of abuse of this drug or of physiological or physical dependence as a result of its use.

CARDOL sotalol hydrochloride 160mg tablet bottle Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cardol sotalol hydrochloride 160mg tablet bottle

alphapharm pty ltd - sotalol hydrochloride, quantity: 160 mg - tablet, uncoated - excipient ingredients: maize starch; sodium starch glycollate; purified talc; magnesium stearate; calcium hydrogen phosphate; povidone - for the prevention and treatment of supraventricular and ventricular arrhythmias.